Production (Stage)
ARS Pharmaceuticals, Inc.
SPRY
$14.98
$0.463.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 4,900.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 4,900.00% | -- |
| Cost of Revenue | -22.70% | 14.34% | 51.07% | -5.72% | -18.88% |
| Gross Profit | 175.03% | 2,529.17% | 17.82% | 12.53% | 18.63% |
| SG&A Expenses | 416.51% | 420.26% | 28.75% | -32.53% | -35.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.25% | 285.14% | 32.47% | -23.16% | -29.58% |
| Operating Income | -181.81% | 561.54% | -20.97% | 25.54% | 29.50% |
| Income Before Tax | -229.77% | 800.64% | -28.67% | 27.94% | 31.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -229.77% | 796.62% | -28.67% | 27.94% | 31.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -229.77% | 796.62% | -28.67% | 27.94% | 31.21% |
| EBIT | -181.81% | 561.54% | -20.97% | 25.54% | 29.50% |
| EBITDA | -179.93% | 562.37% | -20.99% | 25.56% | 29.49% |
| EPS Basic | -224.37% | 787.27% | -26.75% | 29.34% | 32.81% |
| Normalized Basic EPS | -187.80% | 640.48% | -26.75% | 29.37% | 19.86% |
| EPS Diluted | -224.37% | 663.67% | -26.75% | 29.34% | 32.81% |
| Normalized Diluted EPS | -187.80% | 541.52% | -26.75% | 29.37% | 19.86% |
| Average Basic Shares Outstanding | 1.63% | 1.32% | 1.52% | 2.02% | 2.40% |
| Average Diluted Shares Outstanding | 1.63% | 24.01% | 1.52% | 2.02% | 2.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |